FORM 8.3 Amendment – this form replaces RNS number 3946282 , published at 16:03 on 2024-03-14 . Changes have been made to Sections 2(b ). PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code
FORM 8.3 Amendment – this form replaces RNS number 3945654 , published at 19:24 on 2024-03-13 . Changes have been made to Sections 1(f) and 2(b ). PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover
RNS Number : 9333G Harwood Capital LLP 14 March 2024 FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") 1. KEY
RNS Number : 9103G Renalytix PLC 14 March 2024 Renalytix plc (" Renalytix plc " or the "Company") The following correction has been made to the "FORM 8 (OPD)", which was released on 8 March 2024 at 12:14am UK time under RNS no. 1928G. FORM 8 (OPD) PUBLIC OPENING POSITION
RNS Number : 8871G Stifel Nicolaus Europe Limited 14 March 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final
RNS Number : 8846G Stifel Nicolaus Europe Limited 14 March 2024 FORM 8.5 (EPT/RI) REPLACEMENT The Form 8.5 (EPT/RI) - Renalytix announcement released on 13/03/2024 under RNS No 6757G has been amended. Amendments are identified with an asterisk (*).
RNS Number : 7837G Renalytix PLC 14 March 2024 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO. Renalytix plc ("Renalytix" or the "Company")
FORM 8.3 AMENDMENT FOR DISCLOSURE PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Pentwater Capital Management LP (b)
RNS Number : 7712G Polar Capital Holdings PLC 13 March 2024 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of
